Status:
COMPLETED
Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?
Lead Sponsor:
Cumhuriyet University
Conditions:
Lung Neoplasms
Gene, p53
Eligibility:
All Genders
Brief Summary
p53 is a tumor suppressor gene which plays an important role in controlling normal cell proliferation regulation that is located on the chromosome 17 (17p13.1). It is the most common goal of genetic a...
Eligibility Criteria
Inclusion
- patients who were referred to our department with the purpose of 18F-FDG PET/CT imaging for staging due to lung cancer diagnosis
- patients who were performed 18F-FDG PET/CT for diagnosis in the cause of the suspected pulmonary nodule/lesion in thorax CT but not detected pathologic FDG accumulation
- In the control group, healthy subjects with no history of cancer and without any complaint
Exclusion
- Patients had operated for lung cancer, received prior chemotherapy or radiotherapy for lung cancer, with no definitive histological diagnosis, and a blood glucose level greater than 150 mg/dL
Key Trial Info
Start Date :
May 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT02309567
Start Date
May 1 2014
End Date
April 1 2016
Last Update
November 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cumhuriyet University, School of Medicine, department of Nuclear Medicine
Sivas, Campus, Turkey (Türkiye), 58140